Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: john e vanden biesen who wrote (527)	12/2/1997 2:58:00 PM
From: james	Read Replies (1) \| Respond to of 975

Thanks john, how to you like its chance in extended p3 of RA? Do you see any positive data from the last p3? Even though it is not much better than placebo (very few potential drugs are!!!!!), some improvements are there. BLSI decided to go again, a good sign? Another p3 to me means (1)restrict patient-selection (e.g., just pick similar type of patients respond to BLSI, not to placebo) to inflate the stat. (2). improve trial quality. How is its partner's commitment if there is any? Sorry for the long list. The p3 number 40s/30s is interesting. Thanks again regards